Overview

A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis

Status:
Terminated
Trial end date:
2020-12-18
Target enrollment:
Participant gender:
Summary
This study is a Phase 3, multicenter, open-label, long-term safety extension study of Studies C3291032 and C3291031 in Japanese pediatric and adult participants with mild to moderate Atopic Dermatitis (AD).
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer